ArticleBMC women's health2026
HPV and Health-related Quality of Life Scale: Turkish validity and reliability study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to adapt the HPV and Health-Related Quality of Life Scale (HPV-RQOLS) into Turkish and evaluate its reliability and validity.
methodsThis methodological study employed a cross-sectional design and convenience sampling. A total of 150 women diagnosed with HPV who presented to a training and research hospital in Turkey between January and December 2023 were included. The inclusion criteria were age between 18 and 60 years, proficiency in Turkish, a confirmed HPV-positive diagnosis, and voluntary participation in the study. Data were collected using the Participant Diagnosis Form and the HPV and Health-Related Quality of Life Scale (HPV-QoL) and SF-12 Quality of Life Scale. Analyses included content and construct validity through Exploratory Factor Analysis (EFA), Confirmatory Factor Analysis (CFA), internal consistency, concurrent and convergent validity.
resultsThe Confirmatory Factor Analysis conducted in this study demonstrated that the four-factor model of the original scale did not show an adequate fit to the data. In contrast, the three-factor structure of the Turkish version exhibited acceptable fit indices (χ²/df = 2.219, RMSEA = 0.080, GFI = 0.884, AGFI = 0.821, CFI = 0.957). The Turkish HPV-QoL scale was found to comprise three factors-general well-being, health, and sexuality-and this structure explained a statistically significant proportion of the variance (p < 0.01). The contagiousness dimension present in the original scale was removed in the Turkish adaptation based on insufficient factor loadings (< 0.40) and recommendations from the expert panel. Acceptable model fit and high internal consistency were confirmed (total α = 0.938; subscales: 0.807-0.881). The total Cronbach's alpha coefficient of the scale was 0.938, indicating high reliability. Test-retest analyses demonstrated the scale's stability over time (p < 0.05). Furthermore, correlation analysis with the SF-12 Quality of Life Scale revealed a moderate, positive, and statistically significant association (p < 0.05).
conclusionsThe Turkish HPV-QoL scale is a valid and reliable instrument for assessing health-related quality of life in individuals diagnosed with HPV. Its use in clinical practice and research settings may contribute to a better understanding of the psychosocial and physical impacts of HPV on individuals and support the planning of targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.